Journal Article

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Yu, Xianjun, Cheng, Ying, Wang, Wei, Ying, Jieer, Peng, Mengye, Li, Zhiping, Bai, Chunmei, Liu, Tianshu, Deng, Yanhong, Yuan, Ying, Su, Weiguo, Li, Xingya, Jia, Ru, Zhang, Tao, Xiu, Dianrong, Xu, Jianming, Bai, Yuxian, Li, Enxiao, Fan, Songhua, Chen, Jia, Li, Jing, Shen, Lin, Wang, Xiuwen, Xu, Nong, Li, Jie, Qin, Shukui, Tao, Min, Yuan, Xianglin, Zhou, Zhiwei, Chi, Yihebali

2020

Overview

Therapeutic options for advanced neuroendocrine tumours (NETs) are limited. We investigated the efficacy and safety of surufatinib (HMPL-012, sulfatinib) in patients with extrapancreatic NETs. SANET-ep was a randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 24 hospitals across China. Patients (aged 18 years or older) with unresectable or metastatic, well differentiated, extrapancreatic NETs, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and progression on no more than two types of previous systemic regimens were enrolled. Patients were centrally randomly assigned (2:1) using stratified block randomisation (block size 3) via an interactive web response system to receive oral surufatinib at 300 mg per day or matching placebo. Randomisation was stratified by tumour origin, pathological grade, and previous treatment. Patients, investigators, research staff and the sponsor study team were masked to treatment allocation. Crossover to the surufatinib group was allowed for patients in the placebo group at disease progression. The primary endpoint was investigator-assessed progression-free survival, which was analysed in the intention-to-treat population. A preplanned interim analysis was done at 70% of predicted progression-free survival events. This study was registered with ClinicalTrials.gov, NCT02588170. Follow-up is ongoing. Between Dec 9, 2015, and March 31, 2019, 198 patients were randomly assigned to surufatinib (n=129) or placebo (n=69). Median follow-up was 13·8 months (95% CI 11·1–16·7) in the surufatinib group and 16·6 months (9·2–not calculable) in the placebo group. Investigator-assessed median progression-free survival was 9·2 months (95% CI 7·4–11·1) in the surufatinib group versus 3·8 months (3·7–5·7) in the placebo group (hazard ratio 0·33; 95% CI 0·22–0·50; p<0·0001). As the trial met the predefined criteria for early discontinuation of the study at the interim analysis, the study was terminated early, as recommended by the independent data monitoring committee. The most common treatment-related adverse events of grade 3 or worse were hypertension (47 [36%] of 129 patients in the surufatinib group vs nine [13%] of 68 patients in the placebo group) and proteinuria (25 [19%] vs zero). Treatment-related serious adverse events were reported in 32 (25%) of 129 patients in the surufatinib group and nine (13%) of 68 patients in the placebo group. Treatment-related deaths occurred in three patients in the surufatinib group (disseminated intravascular coagulation and hepatic encephalopathy, liver injury, and death with unknown reason) and one patient in the placebo group (cachexia and respiratory failure). Progression-free survival was significantly longer in patients given surufatinib compared with patients given placebo, and surufatinib has a favourable benefit-to-risk profile in patients with progressive, advanced, well differentiated extrapancreatic NETs. Our results suggest that surufatinib might be a new treatment option for this population. Hutchison MediPharma.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Adult / Aged / Angiogenesis Inhibitors - administration & dosage / Angiogenesis Inhibitors - adverse effects / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Cachexia / Chemotherapy / China - epidemiology / Consent / Disease Progression / Disseminated intravascular coagulation / Double-Blind Method / Double-blind studies / Drug-Related Side Effects and Adverse Reactions - classification / Drug-Related Side Effects and Adverse Reactions - pathology / Female / Fibroblasts / Growth factors / Hematology, Oncology, and Palliative Medicine / Hepatic encephalopathy / Humans / Kinases / Laboratories / Male / Medical prognosis / Metastases / Metastasis / Middle Aged / Neoplasm Staging / Neuroendocrine tumors / Neuroendocrine Tumors - drug therapy / Neuroendocrine Tumors - epidemiology / Neuroendocrine Tumors - genetics / Neuroendocrine Tumors - pathology / Oncology / Pancreatic Neoplasms - drug therapy / Pancreatic Neoplasms - epidemiology / Pancreatic Neoplasms - genetics / Pancreatic Neoplasms - pathology / Patients / Peptides / Progression-Free Survival / Proteinuria / Respiratory failure / Survival / Thymus gland / Treatment Outcome